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Summary Using bivariate flow cytofluorometry, we have determined the nuclear DNA distribution and the
expression of the p21 protein (coded by the Ha-ras oncogene) in the bone marrow (BM) cells of five solid
tumour patients having histologically normal BM and in those of 57 patients with plasma cell dyscrasia (28
with monoclonal gammopathies of undetermined significance, MGUS, and 29 with multiple myeloma, MM).
All normal and MGUS and 21/29 (72.4%) MM BM had diploid modal DNA content and 8/29 (27.6%) MM
BM had both diploid and hyperdiploid cell populations. In normal and MGUS BM, the level of the p21
oncoprotein was low and uniform in all G0/GI, S and G2 cells (median fluorescence values in arbitrary units
were 6.1 and 7.5, respectively). The level of p21 was increased both in different aliquots of GO/GI cells and in
the S and G2 cells in diploid MM (median value for GO/GI cells was 20), and especially in MM with
hyperdiploid clones (median value for hyperdiploid cells was 40.5, P<0.005 with respect to normal and
MGUS BM and <0.005 with respect to diploid MM BM). The p21 expression was greater in patients with
advanced (stage III) than in earlier MM (stages I + II) (P <0.005), and it was directly related to the BMPC
infiltration (r = 0.7; P <0.005). Since p21 expression is greater in MM than in both normal and MGUS BM,
Ha-ras could be involved in the malignant plasma cell transformation that distinguishes MM from MGUS.
Plasma cells dyscrasias range from indolent clinical entities
(such as the monoclonal gammopathies of undetermined
significance, MGUS) to true neoplasms, such as multiple
myeloma (MM). The presence of plasma cells monoclonally
coded to secrete a single immunoglobulin (Ig) (monoclonal
component, MC) is the common feature for all entities, but
other biological differences must exist between the plasma
cells of MGUS and those of MM that explain the clinically
different behaviour of these diseases (Barlogie et al., 1989).
Such differences may involve the cellular oncogenes, some
of which probably play a role in transforming the B cell
precursor into a MC secreting plasma cell and in originating
malignancy. For example, the excretion of MC may some-
how be linked with the fact that genetic material from
chromosomes 11, 8 and 18 (where the proto-oncogenes bcl-2
and pim are located) is often translocated at the q32 break-
point of chromosome 14 (Greipp, 1989) where the gene for
the heavy chains of immunoglobulins is coded. Furthermore,
structural changes in chromosomes 1 and 11, where Kirsten-
ras and Harvey-ras genes are located (Gould et al., 1988),
suggest ras oncogene involvement in MM. Actually, Ha-ras
is frequently activated (Neri et al., 1989) and the p21 onco-
protein (coded by Ha-ras) is overexpressed in this disease,
mainly when it is in advanced phase (Tsuchiya et al., 1988).
We have started to investigate the oncogene expression in
plasma cell dyscrasias using bivariate flow cytometry (FCM).
This technique simultaneously measures the fluorescence of a
monoclonal antibody (MoAb) against the protein coded by
the oncogene (oncoprotein) under study and the nuclear
DNA distribution (Andreeff et al., 1986; Giordano et al.,
1989), thus allowing the oncoprotein levels to be evaluated
both in cell cycle phases and in distinct plasma cell popula-
tions identified according to their DNA content (Watson,
1986; Stewart, 1989). This paper refers data obtained on the
p21 oncoprotein coded by Ha-ras.
Materals and methods
Using bivariate FCM, we determined the nuclear DNA con-
tent and the p21 expression in the BM cells of five solid
tumour patients (two non small cell lung, two breast and one
gastric metastatic carcinomas) having no BM involvement and
in those of 57 patients with plasma cell dyscrasia (28 with
MGUS and 29 with MM) who underwent BM aspiration for
diagnostic purposes at Clinica Medica II of the University of
Pavia between January 1988 and June 1989 (Table I).
The complete clinical, radiological and laboratory evalua-
tion of patients with plasma cell dyscrasias was carried out
according to a protocol that also require special examina-
tions, such as P2-microglobulin and thymidine kinase level
determination (Ucci et al., 1987) and BMPC proliferative
activity evaluation (as the percentage labelled with in vitro
BUDR and with the monoclonal antibody Ki-67). In all
patients, BMPC% was counted on imprints of BM sample
aspirated for FCM and p21 evaluation. Diagnosis of MM
required the presence of at least two of the following three
features: (a) serum and/or urine monoclonal component
(MC); (b) BMPC greater than 20%; (c) osteolytic lesions on
plain skeletal X-ray. Patients with a serum and/or urine MC
but not fulfilling the other two criteria were considered as
having MGUS.
Nineteen MM patients were studied at presentation (stag-
ing was performed according to Durie & Salmon, 1975) and
ten at first relapse after having received melphalan-
prednisone induction and maintenance.
Table I Clinical features at diagnosis of patients included in this
study
No. of pts
MGUS MM
Studied patients 28 29
M/F 17/11 15/14
Age, years (median) 64 61
IgG 22 18
IgA 4 8
IgD - I
IgM 2 -
LC only - 2
LC type
K 17 19
L 11 10
Stage I 3
Stage II 10
Stage III 16
MM = multiple myeloma; MGUS = monoclonal gammopathies of
undetermined significance; LC = light chain; stage according to
Durie and Salmon.
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DNA staining
A separate single DNA measurement was performed for each
sample, using a slightly modified (Riccardi et al., 1986)
Krishan's staining technique (Krishan, 1975). As soon as
aspirated, 3 to 5 BM particles were first placed on a sloping
slide and gently washed with saline to eliminate peripheral
blood contamination completely. They were then suspended
in 2 ml of phosphate buffered saline (PBS, Hoechst AG,
West Germany) and vigorously drawn through needles of
decreasing diameter to obtain a cell suspension. Cell counts
were made so as to have more than I04 cells ml-1 per sample.
The suspension was centrifuged and the pellet stained with
propodium iodide (PI, Calbiochem, Behring Corp., San
Diego, CA, USA) at a concentration of 50 tg ml1' in PBS;
0.1% Nonidet P40 (Calbiochem) and 0.05% RNAse (type
IA, from bovine pancreas, Sigma) were included in the stain-
ing solution. A 30 min staining time at room temperature
provided the best histogram resolution. Finally, cells were
filtered through a 35 jam nylon mesh to remove aggregates
prior to flow analysis. Fresh WBC from healthy donors were
used as an internal diploid reference standard.
Immunofluorescent staining ofanti-p21 ras antibody
Following BM aspiration, light-density mononuclear cells
(LDMNCs) were collected after centrifugation on a Ficoll-
Hypaque gradient; density 1,077 g cm-3 (Pharmacia Fine
Chemicals, Piscataway, NJ, USA) in Iscove's modified
Dulbecco's medium (IMDM, GIBCO). The suspensions were
further purified by removing adherent cells and T-
lymphocytes. A 5 ml suspension of light density cells at a
concentration of 5 x 106cells ml' IMDM plus 15% FCS
was incubated in 25cm2 tissue culture flasks for 60 min at
37°C, and nonadherent cells carefully collected. This pro-
cedure was repeated twice. T-lymphocyte depleted LDMNCs
(T-LDMNCs) were obtained by rosetting MNC suspensions
(5 x 106cells) with 2-aminoethylisothiouronium bromide
(AET, Sigma Chemical Co., St Louis, USA) treated sheep
red blood cells in a 5% suspension with IMDM. Non-
rosetting cells were separated by a second Ficoll-Hypaque
density centrifugation. Viability after cell separation was
evaluated by the Trypan blue dye exclusion test. Lastly the
samples were fixed with 70% cold ethanol (4C) for at least
30 min. After removal of the fixative, 2 x 106 cells were
washed in PBS and incubated with a 1:4 dilution of the
anti-p21 Ha-ras sheep polyclonal antibody affinity purified
with synthetic peptide (with a specificity of a 20 amino acid
sequence in p21 Ha-ras) (BIOTX Corp. Mineola, USA,
Distr. Diasint - Florence, I) in PBS and 0.5% normal sheep
serum (NSS, Flow Laboratories) for 30 min at room
temperature.
Using Harvey murine sarcoma virus-transformed normal
rat kidney cell lines (Ha-NRK) and the human acute T-cell
leukaemia cell line Molt-4, we confirmed the specificity of the
anti-Ha-ras antibody, by immunoblotting with the biotin
avidin rabbit anti-sheep peroxidase system (Vector
Laboratories, Burlingame, CA). The reactivity and the
localisation of the antibody were also determined by
fluorescence microscopy using Ha-NRK and Molt 4 cells
stained according the two-step indirect immunofluorescence
method described below. This antibody is especially suited
for immunofluorescence and DNA-correlated flow cytometric
determination, since ethanol can be used as a fixative and
this generally provides the best preservation of morphology,
DNA content and the most intense immunofluorescence sig-
nals. In contrast, methanol fixation is required when using
the FV132-62 mouse MoAb generated against human Ha-, Ki-
and N-ras p21.
Cells were next centrifuged and incubated for 15 min in
PBS/NSS. Then they were washed in PBS and resuspended in
a 1:50 dilution of FITC-conjugated rabbit anti-sheep IgG
MoAb (Sigma Chem.). Cells incubated with NSS plus
labelled second antibody or with labelled second antibody
only served as control for background fluorescence.
Counterstaining of double-stranded DNA was done with
PI. Cells labelled with FITC-conjugated Abs were washed
twice in PBS and incubated for 10min in PBS containing
0.1% Triton X-100 (Hoechst AG, Germany). Two ml PBS
containing 5lag ml1' PI and 0.05% RNAse were then added
for at least 30 min. Finally, cells were filtered through a
35lam nylon mesh to remove aggregates prior to flow
analysis.
DNAflow cytometry
Single DNA analysis was performed with a Partec PAS II
(Basel, Switzerland) arc lamp flow cytometer, with data
recorded on a dedicated Hewlett Packard computer and dis-
played as frequency histograms. To construct each histogram
10,000 to 40,000 cells were analysed. The measuring condi-
tions included the following: an HBO 100 W/2 (Osram)
excitation source with KGI (2 mm) and BG38 (4 mm) filters;
an interference filter of 546 ± 12 nm; a TK 590 dichromatic
mirror and a K 610 barrier filter to select the emitted red
fluorescence. The coefficient of variation (CV) for the GO/GI
peaks was evaluated as the width at half maximum of the
peak divided by the peak mean channel and the factor 2.35.
For ploidy evaluation, BM cells were analysed either alone
or after they had been mixed with an aliquot of PBL, which
was employed both to calibrate the instrumentation and as a
diploid standard. Aneuploidy was estimated from the DNA-
index (DNA-I) value, i.e. the ratio between the model chan-
nel of the GO/G1 peak of the sample under study and the
modal channel of the GO/G1 peak of the reference standard.
For a diploid cell population the DNA-I = 1.00. According
to an international convention (Hiddeman et al., 1984), only
the samples which gave at least two separate GO/GI peaks
were considered aneuploid.
DNA/p2Jflow cytometry
Bivariate FCM (FITC-green vs PI-red) was performed with a
FACS Star Cell Sorter (Becton Dickinson FACS Systems,
Sunnyvale, CA, USA). Excitation of the FITC-labelled cells
and the DNA-associated PI was accomplished with an
Innova 90-5 argon ion laser (Coherent, Palo Alto, CA, USA)
tuned to 488 nm and operated at 300 mW. Emitted
fluorescence was split into two bands (green and red) by
means of a dichromatic mirror DM 560: green fluorescence
was measured through an interference filter 525 (30 nm
h.b.w.), while the red was measured after a long pass filter
620. Instrumentation setting and calibration were performed
daily using 1.33Itm fluorescent microspheres (Polysciences,
Warrington, PA, USA).
Data were collected (on a log scale but also converted to a
linear scale for comparing differences between experiments)
with a Consort 30 (Becton Dickinson FACS System) soft-
ware program running on a dedicated Hewlett Packard com-
puter and displayed as two-parameter contour density plots.
Sequential contours represented increasing isometric
equivalents of 5, 15, 30, 60, 120 and 200 cells. A total of
20,000 cells were analysed for each contour plot.
The expression of the antigens studied in the GO/GI, S and
G2-M phases of the cell cycle was evaluated from the mean
green fluorescence intensity of the corresponding FITC-
labelled antibody (inside operationally gated areas) and ex-
pressed as mean channel numbers. The same green
fluorescence values for the corresponding boxes in matched
control samples were also calculated. The 'net' fluorescence
intensity associated with the specific staining was calculated
by subtracting the nonspecific fluorescence.
Statistical analysis
The correlations between Ha-ras p21 fluorescence levels and
other parameters were examined by the Student's t and x2
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Figure 1 Representative histograms of flow cytometric DNA
aneuploid MM.
Results
The results obtained are shown in Figures 1-6.
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of the hyperdiploid clone was 1.50 and the range was from
1.21 to 1.92).
DNAflow cytometry
BMPC% of samples used for FCM analysis ranged from 5
to 18% (median 9%) in MGUS and from 29 to 95%
(median 55%) while it was lower than 3% in all normal BM
samples. All samples were evaluable by FCM and high-
quality DNA profiles were obtained. The values of CV
ranged from 2.2 to 3.3 (median = 2.5) for the control samples
and from 2.5 to 4.2 (median = 2.8) for the GO/G1 peak of
the patients' bone marrow samples (Figure 1).
All normal and MGUS BM samples had diploid DNA
content (i.e. the DNA-I of the GO/GI peak ranged from 0.95
to 1.12, with no additional peak when normal WBC were
added to the BM population as an internal standard).
Among MM, 21/29 (72.4%) had a single-cell population with
diploid DNA content and 8/29 (27.6%) had two cell clones,
one diploid and the other hyperdiploid (the median DNA-I
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Figure 2 Dual staining of p21 Ha-ras protein expression and
DNA content in normal bone marrow cells.
DNA/p2J flow cytometry
Cell clumping was negligible and bright, specific immuno-
fluorescent staining (from FITC-labelled antibodies) was
obtained. The fluorekence intensity of tumour cells sequen-
tially treated with sheep anti-p21 ras antibody and FITC-
labelled goat anti-sheep IgG antibody was strikingly higher
than in control samples, i.e. samples of cells exposed to NSS
and labelled second antibody or to second antibody only.
Figures 2-5 show representative cytograms of the bivariate
analysis of the p21 oncoprotein levels (expressed as mean
fluorescence of the GO/GI peak in arbitrary units) versus the
DNA content in normal BM cells, in MGUS and in diploid
and aneuploid MM.
In normal and MGUS BM, the p21 oncoprotein level of
the GO/GI cells was consistently low and uniform along the
cell cycle (Figures 2 and 3).
In diploid MM, the expression of p21 was more
.a
[I..
,. ;..... ....-..
S
t - *^;
....
; R K
IIM
.2N 4W
~~DM cu,.. ...imT^,. ,s.....j-
Figure 3 Correlated DNA/Ha-ras p21 FCM analysis of bone
marrow cells from MGUS. The p21 oncoprotein expression is
slightly higher than in the normal bone marrow and again evenly
distributed along the cell cycle.784 M. DANOVA et al.
heterogeneous. The p21 level was increased (with respect to
the level observed in normal and MGUS BM) in at least a
part of the GO/GI cells and these high levels were maintained
in the S and G2-M phase cells (Figure 4).
In MM with both diploid and hyperdiploid plasma cells,
the p21 expression was distinctly greater in the cell popula-
tion with higher DNA content than in the diploid population
(Figure 5). The median value (in arbitrary units) of p21
expression for the hyperdiploid clone was 40.5 (range 24-57)
which was higher than that found in diploid MM (median
20; range 9.5-30; P <0.005). These values were both
significantly higher than those found in MGUS (median 7.5;
range 3.5-11; P <0.005) and normal BM (median 6.1; range
2.0-8.3; P<0.005) (Figure 6).
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Figure 6 p21 Ha-ras expression levels in normal bone marrow,
in MGUS in diploid and in aneuploid MM.
disease (presentation or relapse), haemoglobin, levels of
serum calcium, type of MC, P2-microglobulin, thymidine
kinase or proliferative activity (evaluated as percentage of
plasma cells labelled with in vitro BUDR and with the
monoclonal antibody Ki-67).
Discussion
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Figure 4 Same analysis performed in diploid MM. The p21
oncoprotein expression is low and uniformly expressed along the
cell cycle and, again, there is no clear correlation with a partic-
ular phase of the cycle.
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Figure 5 Bone marrow cells from a patient with MM in active
phase and with abnormal DNA content. The histogram on the
left shows two cell populations with different DNA content and
the cytogram on the right their p21 Ha-ras expression. The
population with higher DNA content also has higher p21 Ha-ras
expression.
Correlation between p21 expression and clinical and laboratory
parameters in MM
The p21 expression was greater in patients with advanced
(stage III) than in earlier MM (stages I + II) (P <0.005) and
it was directly related to BMPC infiltration (r = 0.7;
P <0.005). No differences in p21 expression were found to
be dependent on patient age, type of MC, phase of the
Our data suggest that Ha-ras is involved in the malignant
plasma cell transformation that distinguishes MM from
MGUS. In fact, the p21 oncoprotein coded by this oncogene
is overexpressed in MM (as a confirmation that this
oncogene is activated in MM) (Neri et al., 1989), but not in
MGUS, where malignancy is not obvious. Other molecular
mechanisms may account for the DNA rearrangement
leading to the production of monoclonal immunoglobulin,
which is the common feature of both MM and MGUS.
Intact proto-oncogenes normally affect cell growth and/or
differentiation by producing regulatory proteins (that often
share some specificity for individual cell types and cell cycle
states). Alteration of oncogene structure may cause malig-
nancy, due to overproduction, increased specific activity or
deregulated synthesis of these proteins (Cooper, 1982;
Bishop, 1983; Varmus, 1984). The usual techniques for study-
ing oncogene structure and/or function include blotting
studies of DNA or of its RNA message and investigation of
the biochemical function of protein products. Immunoblot-
ting studies indicate that ras genes are probably involved in
(normal) growth control (Shih & Weeks, 1984; McGrath et
al., 1984; Sweet et al., 1984; Bar-Sagi, 1989) and that their
alteration plays a role in causing several types of human
haematological and solid tumours (Viola et al., 1985; Thoret
et al., 1984; Lundy et al., 1986; Thein et al., 1986; Liu et al.,
1987; Bos et al., 1987; Senn et al., 1988; Pedersen-Bjegard et
al., 1988; Hirai et al., 1988).
The technique we used evaluates the presence of an
oncogene product in the cells without furnishing data either
on the oncogene structure or on the product function. How-
ever, there are several advantages with this technique. Based
on a MoAb against the oncogene product, bivariate FCM
quantitates its expression simultaneously with DNA distribu-
tion, and this allows protein expression to be determined
both in different cell cycle phases and in distinct cell popula-
tions identified according to their DNA content (Danova et
al., 1988). There have been technical difficulties in obtaining
good specific fluorescences for both the MoAb against the
protein and good DNA resolution, but they were overcome
with the fixation-permeabilisation technique we utilised
(Giordano et al., 1989).
The median p21 expression (that was observed in all cell
cycle phases) was low in normal and in MGUS BM and
distinctly greater in diploid and especially in hyperdiploid
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MM cells (where Ha-ras has already been found to be
activated frequently) (Neri et al., 1989; Tsuchiya et al., 1988).
A suggestion is that Ha-ras alteration is involved in the
molecular events leading a plasma cell (already monoclonally
determined to MC production in both MGUS and MM) to
become a malignant cell as well.
There are several indications that plasma cells progres-
sively change their biological properties from those of normal
to MM cells. In MGUS, plasma cells are already abnormal
in that they secrete a MC, but they are not malignant. The
subsequent malignant transformation of MGUS into MM is
a well known event. Finally, clonal selection occurs during
the course of MM, with hyperdiploid clones becoming
predominant (whereas they had been percentually small at
diagnosis) or with the appearance of new hyperdiploid clones
(Montecucco et al., 1984). Data from our study indicate that
p21 expression progressively increases from MGUS to dip-
loid, to hyperdiploid MM, thus paralleling the progressively
malignant behaviour of plasma cells.
There are possible clinical implications for p21 expression
studies. In our cases, the p21 expression was greater in
advanced (stage III) MM and closely related with BMPC
infiltration. Alpha-interferon reverses a number of trans-
formed, tumorigenic cell lines (Brouty-Boye et al., 1985) and
some reversions are associated with a significant reduction in
the expression of the oncogenes implicated in the transforma-
tion process (Lin et al., 1983; Samid et al., 1984). If we
speculate that the effectiveness of this agent in MM is due to
a similar mechanism, its activity may be evaluated with the
FCM method we employed to detect p21 expression. Of
course, the clinical meaning of both the presence and the
degree of p21 expression in plasma cells dyscrasias, and
especially in MM, needs large studies for final confirmations.
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